Collaboration with GeneQuantum follows Samsung Biologics' recent partnership with China-based biotech company APRINOIA Therapeutics
Samsung Biologics partners with GeneQuantum. (Credit: Adam Radosavljevic from Pixabay.)
Samsung Biologics has partnered with Chinese biotech company GeneQuantum Healthcare to jointly develop an antibody-drug conjugate (ADC) to treat certain cancer types.
The partnership will focus on the development of ADC for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumours.
Also, the new collaboration with GeneQuantum follows Samsung Biologics’ recent partnership with biotech company APRINOIA Therapeutics and indicates its entry and footprint in the Chinese market.
Samsung Biologics CEO Tae Han Kim said: “We are extremely proud that our CDO capabilities are continuously being recognized in the Chinese market, especially amid the current global climate.
“By joining forces with a leading biotech company with a distinguished reputation in the market, we hope to further expand on the partnership to provide effective and affordable treatments for patients with unmet medical needs.”
GeneQuantum secured FDA IND approval for its anti-HER2 ADC asset
GeneQuantum Healthcare is a privately held biotech company engaged in the development of advanced biologic drugs.
The biotech firm has recently received the FDA Investigational New Drug (IND) Good to Proceed Letter for its anti-HER2 ADC asset, manufactured using the company’s patented intelligent ligase-dependent conjugation (iLDC) technology platform.
GeneQuantum had previously awarded a CDO contract to its CDMO partner for the first asset and has selected Samsung Biologics for its second antibody candidate.
The company has selected Samsung Biologics based on its capacity to develop the products in less time its original cell line technology, S-CHOice, which improves titers up to two-fold.
GeneQuantum CEO Gang Qin said: “GeneQuantum is excited to collaborate with Samsung Biologics, a global leading partner with proven development capabilities in the market.
“One of the decision-making aspects for this partnership was Samsung Biologics’ dedication and commitment to providing high-quality services. With this mutually beneficial partnership, we aim to further expand on this development scope to bring innovative treatments for patients.”